What CollPlant (CLGN) share and RSU holdings are disclosed for the CEO?

The filing lists 31,137 CollPlant Ordinary Shares directly held by Tal Yehiel, plus 80,000 restricted share units. Of these RSUs, 25,000 are already vested and 55,000 are scheduled to vest over time, subject to his continued service with the company.

How do the CLGN CEO’s restricted share units vest over time?

According to the filing, 25,000 restricted share units are vested and 55,000 will vest in eleven equal quarterly installments. The vesting period runs from March 25, 2026 through September 25, 2028, contingent on Tal Yehiel’s continued service.

CollPlant CEO Tal Yehiel files initial Form 3

CollPlant Biotechnologies Ltd director and Chief Executive Officer Tal Yehiel filed an initial ownership report.

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

CollPlant Biotechnologies Ltd director and Chief Executive Officer Tal Yehiel filed an initial ownership report. The filing lists direct holdings of options to purchase Ordinary Shares, including grants exercisable at $4.0200 and $6.3900 per share with expirations between 2028 and 2032, covering 75,000, 37,800, 81,266 and 100,000 underlying shares. Yehiel also reports 31,137 Ordinary Shares and 80,000 restricted share units, of which 25,000 are vested and 55,000 are scheduled to vest in eleven equal quarterly installments from March 25, 2026 through September 25, 2028, subject to continued service. Certain awards are held through a trustee to qualify for Israeli Section 102 tax benefits.

Insider Trade Summary

6 transactions reported

Mixed 6 txns

Insider Tal Yehiel

Role Chief Executive Officer

Type	Security	Shares	Price	Value
holding	Options to Purchase Ordinary Shares	--	--	--
holding	Options to Purchase Ordinary Shares	--	--	--
holding	Options to Purchase Ordinary Shares	--	--	--
holding	Options to Purchase Ordinary Shares	--	--	--
holding	Ordinary Shares	--	--	--
holding	Restricted Share Units	--	--	--

Holdings After Transaction: Options to Purchase Ordinary Shares — 294,066 contracts (Direct); Ordinary Shares — 31,137 shares (Direct); Restricted Share Units — 80,000 shares (Direct)

Footnotes (4)

F1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's Share Ownership and Option Plan (2010) or 2024 Share Award Plan must be registered in the name of a trustee.
F2. Of the restricted share units reported herein, 25,000 units are vested, and the remaining 55,000 units vest in eleven equal quarterly installments beginning March 25, 2026 and ending September 25, 2028, subject to the Reporting Person's continued service to the Issuer as of such vesting date.
F3. Fully vested and exercisable.
F4. 93,750 options are fully vested and exercisable and the remaining 6,250 vest is May 2, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 3 filing show for CollPlant Biotechnologies (CLGN) CEO Tal Yehiel?

The Form 3 shows Tal Yehiel’s initial ownership in CollPlant, including options, ordinary shares, and restricted share units. It establishes his starting equity position as director and Chief Executive Officer, rather than reporting any new share purchases or sales.

How many options does the CLGN CEO report holding in this Form 3?

Tal Yehiel reports several option grants to purchase CollPlant Ordinary Shares, including awards exercisable at $4.0200 and $6.3900 per share. These cover 75,000, 37,800, 81,266 and 100,000 underlying shares, with expiration dates between 2028 and 2032.

Why are some CollPlant (CLGN) equity awards held through a trustee?

The filing explains that certain securities issued to employees or directors must be registered in a trustee’s name. This structure is required to qualify for specific tax benefits under Section 102 of the Israeli Tax Ordinance for CollPlant’s share ownership and option plans.

Does this CollPlant (CLGN) Form 3 indicate insider buying or selling activity?

No, the Form 3 functions as an initial ownership statement for Tal Yehiel. It records existing holdings in options, ordinary shares, and restricted share units, without reporting new open-market purchases, sales, or other transactional changes in his equity position.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 03/19/2026 - 04:29 PM EDT

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Tal Yehiel

(Last)

(First)

(Middle)

C/O COLLPLANT BIOTECHNOLOGIES LTD.

4 OPPENHEIMER ST, WEIZMANN SCIENCE PARK

(Street)

REHOVOT

7670104

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/19/2026

3. Issuer Name and Ticker or Trading Symbol
CollPlant Biotechnologies Ltd [ CLGN ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Executive Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	31,137	D
Restricted Share Units⁽¹⁾	80,000⁽²⁾	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Options to Purchase Ordinary Shares⁽¹⁾⁽³⁾	01/14/2019	01/14/2028	Ordinary Shares	75,000⁽³⁾	$4.02	D
Options to Purchase Ordinary Shares⁽¹⁾⁽³⁾	05/18/2020	07/31/2028	Ordinary Shares	37,800⁽³⁾	$4.02	D
Options to Purchase Ordinary Shares⁽¹⁾⁽³⁾	05/26/2021	05/26/2030	Ordinary Shares	81,266⁽³⁾	$6.39	D
Options to Purchase Ordinary Shares⁽¹⁾⁽⁴⁾	05/02/2023	05/02/2032	Ordinary Shares	100,000⁽⁴⁾	$6.39	D

Explanation of Responses:

1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee or director in connection with the Issuer's Share Ownership and Option Plan (2010) or 2024 Share Award Plan must be registered in the name of a trustee.

2. Of the restricted share units reported herein, 25,000 units are vested, and the remaining 55,000 units vest in eleven equal quarterly installments beginning March 25, 2026 and ending September 25, 2028, subject to the Reporting Person's continued service to the Issuer as of such vesting date.

3. Fully vested and exercisable.

4. 93,750 options are fully vested and exercisable and the remaining 6,250 vest is May 2, 2026, subject to the Reporting Person's continued service to the Issuer as of such vesting date.

	/s/ Yehiel Tal	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR